Michael Cloonan's most recent trade in Sionna Therapeutics Inc. was a trade of 436,100 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 436,100 | 436,100 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2025 | 33,532 | 53,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 37.31 per share. | 21 Oct 2025 | 33,532 | 547,343 | - | 37.3 | 1,251,079 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 21 Oct 2025 | 33,532 | 580,875 | - | 6.1 | 204,881 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 21 Oct 2025 | 30,049 | 577,392 | - | 6.1 | 183,599 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2025 | 30,049 | 109,569 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 35.63 per share. | 21 Oct 2025 | 30,049 | 547,343 | - | 35.6 | 1,070,646 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2025 | 22,895 | 86,674 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 36.60 per share. | 21 Oct 2025 | 22,895 | 547,343 | - | 36.6 | 837,957 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 21 Oct 2025 | 22,895 | 570,238 | - | 6.1 | 139,888 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 34.44 per share. | 21 Oct 2025 | 13,324 | 547,343 | - | 34.4 | 458,879 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 21 Oct 2025 | 13,324 | 560,667 | - | 6.1 | 81,410 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2025 | 13,324 | 139,618 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 15 Oct 2025 | 14,775 | 562,118 | - | 6.1 | 90,275 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 14,775 | 163,367 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 31.11 per share. | 15 Oct 2025 | 14,775 | 547,343 | - | 31.1 | 459,662 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 10,225 | 153,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 31.46 per share. | 15 Oct 2025 | 10,225 | 547,343 | - | 31.5 | 321,691 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 15 Oct 2025 | 10,225 | 557,568 | - | 6.1 | 62,475 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 200 | 152,942 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 15 Oct 2025 | 200 | 547,343 | - | 34 | 6,800 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 15 Oct 2025 | 200 | 547,543 | - | 6.1 | 1,222 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 28.85 per share. | 26 Sep 2025 | 17,207 | 547,343 | - | 28.8 | 496,346 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Sep 2025 | 17,207 | 564,550 | - | 6.1 | 105,135 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2025 | 17,207 | 185,935 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2025 | 7,793 | 178,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 29.70 per share. | 26 Sep 2025 | 7,793 | 547,343 | - | 29.7 | 231,451 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Sep 2025 | 7,793 | 555,136 | - | 6.1 | 47,615 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 24.96 per share. | 26 Aug 2025 | 17,574 | 547,343 | - | 25.0 | 438,647 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Aug 2025 | 17,574 | 564,917 | - | 6.1 | 107,377 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 17,574 | 210,568 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 26 Aug 2025 | 7,426 | 547,343 | - | 25.0 | 185,714 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Aug 2025 | 7,426 | 554,769 | - | 6.1 | 45,373 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 7,426 | 203,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2025 | 25,000 | 228,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 20 Aug 2025 | 25,000 | 572,343 | - | 6.1 | 152,750 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 20 Aug 2025 | 25,000 | 547,343 | - | 22.8 | 568,750 | Common Stock |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 450,252 | 450,252 | - | - | Stock Option (Right to Buy) |